Givinostat

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Duchenne Muscular Dystrophy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Polycythemia Vera · Phase 3 · investigational in the US

Also approved (2)
EU
  • Duvyzat is indicated for the treatment of Duchenne muscular dystrophy (DMD) in ambulant patients, aged 6 years and older, and with concomitant corticosteroid treatment.
Product first approved 2025EMA
UK
  • Duchenne muscular dystrophy in patients aged 6 years and older, all genetic variants
Product first approved 2024MHRA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Duchenne Muscular Dystrophy
NCT05933057 · Italfarmaco
2024-02-19 – 2028-02 · Duchenne Muscular Dystrophy
What this study did
Polycythemia Vera
Phase 2/3 (1)
Duchenne Muscular Dystrophy
NCT03373968 · Italfarmaco
2017-10-24 – 2029-12 · Duchenne Muscular Dystrophy
What this study did
Phase 2 (10)
Duchenne Muscular Dystrophy
NCT06769633 · Italfarmaco
2025-01-02 – 2029-12 · Duchenne Muscular Dystrophy
What this study did
Polycythemia Vera
NCT00928707 · Italfarmaco
2009-06 – 2011-10 · Polycythemia Vera
What this study did
Other / comorbidity
NCT01761968 · Italfarmaco
2013-03 – 2026-12 · Chronic Myeloproliferative Neoplasms
What this study did
NCT03238235 · Italfarmaco
2018-01-09 – 2021-03-19 · Becker Muscular Dystrophy
What this study did
NCT00570661 · Italfarmaco
2006-09-12 – 2013-06-10 · Active Systemic, Onset Juvenile Idiopathic Arthritis
What this study did
NCT01261624 · Italfarmaco
2010-10 – 2013-03 · Polyarticular Course Juvenile Idiopathic Arthritis
What this study did
NCT00792506 · Italfarmaco
2008-10 – 2010-07 · Multiple Myeloma
What this study did
NCT00792831 · Italfarmaco
2008-02 – 2009-04 · Chronic Lymphocytic Leukemia
What this study did
NCT00606307 · Italfarmaco
2007-12 – 2008-12 · Myeloproliferative Diseases
What this study did
NCT00442182 · Radboud University Medical Center
started 2006-09 · Autoinflammatory Syndromes, HIDS, TRAPS, Schnitzler's Syndrome
What this study did
Phase 1/2 (5)
Duchenne Muscular Dystrophy
NCT01761292 · Italfarmaco
2013-04 – 2017-11 · Duchenne Muscular Dystrophy (DMD)
What this study did
Polycythemia Vera
NCT01901432 · Italfarmaco
2013-10 – 2017-09-25 · Polycythemia Vera
What this study did
Other / comorbidity
NCT00792467 · Italfarmaco
2008-02 – 2010-09 · Hodgkin's Lymphoma
What this study did
NCT00792740 · Italfarmaco
2007-10-22 – 2009-03-11 · Crohn's Disease
What this study did
NCT00496431 · Italfarmaco
2007-05 – 2009-03 · Hodgkin's Lymphoma
What this study did
Phase 1 (5)
Other / comorbidity
NCT06736223 · Italfarmaco
2025-05-29 – 2025-08-14 · Hepatic Impairment
What this study did
NCT05845567 · Italfarmaco
2022-03-21 – 2022-05-24 · Drug Drug Interaction
What this study did
NCT05492318 · Italfarmaco
2022-03-21 – 2022-05-24 · Drug-Drug Interaction, Heathy Volunteer
What this study did
NCT05860114 · Italfarmaco
2022-03-21 – 2022-05-24 · Drug Drug Interaction
What this study did
NCT04821063 · Italfarmaco
2021-04-13 – 2021-06-18 · Duchenne and Becker Muscular Dystrophy, Polycytemia Vera
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT01557452 · Italfarmaco
2011-12-28 – 2014-01-27 · Juvenile Idiopathic Arthritis
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Duchenne Muscular Dystrophy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Givinostat: this drugApprovedSmall moleculeHDACReliable signal
NCT02851797: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months): Givinostat 1.27 seconds (Standard Error 0.04) | Placebo 1.48 seconds (Standard Error 0.058)
Romidepsin
Approved(overall)
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication
Vorinostat
Approved(overall)
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication
Panobinostat
US approval withdrawn(overall)
Small moleculeHDAC
Partial signal(overall)
No reviewed efficacy summary in this indication
Chidamide
Phase 3(overall)
Small moleculeHDAC
Reliable signal(overall)
No reviewed efficacy summary in this indication
DeramiocelPhase 3Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
Purinostat Mesylate
Phase 3(overall)
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication
RGX-202Phase 2/3Gene therapy / editingDystrophin (microdystrophin transgene)not yet gradedNo reviewed efficacy summary in this indication
Delpacibart ZotadirsenPhase 2RNA / oligonucleotideDMD exon 44not yet gradedNo reviewed efficacy summary in this indication
BampidirsenPhase 1/2RNA / oligonucleotideDMD exon 53not yet gradedNo reviewed efficacy summary in this indication
Nivudirsen (BMN 351)Phase 1/2RNA / oligonucleotideDMD exon 51not yet gradedNo reviewed efficacy summary in this indication
REC-2282
Discontinued
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Givinostat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Chronic Myeloproliferative NeoplasmsActive not recruiting
Est. primary completion 2026-12 · NCT01761968 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Phase 3Duchenne Muscular DystrophyRecruiting
Est. primary completion 2028-02 · NCT05933057 · CT.gov ↗
What to watch
2029 (2)
December 2029 (2)
Phase 2Duchenne Muscular DystrophyRecruiting
Est. primary completion 2029-12 · NCT06769633 · CT.gov ↗
What to watch
Phase 2/3Duchenne Muscular DystrophyRecruiting
Est. primary completion 2029-12 · NCT03373968 · CT.gov ↗
What to watch

See the full readout calendar ↗